Last reviewed · How we verify
NCT03271281
PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2
Phase 2 trial testing One injection of 68Ga-NODAGA-E[c(RGDyK)]2 in Neuroendocrine Tumors in 113 participants. Completed in 31 December 2021.
31 December 2021
Quick facts
| Lead sponsor | Rigshospitalet, Denmark |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 113 |
| Start date | 4 December 2017 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- One injection of 68Ga-NODAGA-E[c(RGDyK)]2 — full drug profile →
- PET/CT
Conditions studied
- Neuroendocrine Tumors — all drugs for Neuroendocrine Tumors →
Sponsor
Rigshospitalet, Denmark
Who can join
18 and older, any sex, with Neuroendocrine Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of angiogenesis PET/CT with the radioligand 68Ga-NODAGA- E\[c(RGDyK)\]2 in patients with neuroendocrine tumors (NETs).
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.
Xiao W, Jiang W, Chen Z, Huang Y, et al · · 2025 · cited 144× · PMID 40038239 · DOI 10.1038/s41392-024-02107-5 -
Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?
Fu C, Yu L, Miao Y, Liu X, et al · · 2023 · cited 121× · PMID 36873165 · DOI 10.1016/j.apsb.2022.07.020 -
Peptide-Drug Conjugates: A New Hope for Cancer Management.
Chavda VP, Solanki HK, Davidson M, Apostolopoulos V, et al · · 2022 · cited 59× · PMID 36364057 · DOI 10.3390/molecules27217232 -
Targeting Integrins with Radiolabeled RGD Analogues for Radiotheranostics of Metastatic Radioactive Iodine Nonresponsive Thyroid Cancer: New Avenues in Personalized Medicine.
Klubo-Gwiezdzinska J, Chen X. · · 2020 · cited 12× · PMID 32122272 · DOI 10.1089/thy.2020.0169 -
Prospective Phase II Trial of [<sup>68</sup>Ga]Ga-NODAGA-E[c(RGDyK)]<sub>2</sub> PET/CT Imaging of Integrin α<sub>v</sub>β<sub>3</sub> for Prognostication in Patients with Neuroendocrine Neoplasms.
Carlsen EA, Loft M, Loft A, Czyzewska D, et al · · 2023 · cited 11× · PMID 35981899 · DOI 10.2967/jnumed.122.264383 -
EGFR- and Integrin α<sub>V</sub>β<sub>3</sub>-Targeting Peptides as Potential Radiometal-Labeled Radiopharmaceuticals for Cancer Theranostics.
Rodrigues Toledo C, Tantawy AA, Lima Fuscaldi L, Malavolta L, et al · · 2024 · cited 6× · PMID 39126121 · DOI 10.3390/ijms25158553 -
Mechanical Signaling: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets.
Long Y, Wang P, Lei J, Su B, et al · · 2025 · cited 4× · PMID 41377763 · DOI 10.1002/mco2.70523
Verify or expand the search:
- PubMed search for NCT03271281
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of One injection of 68Ga-NODAGA-E[c(RGDyK)]2
Trials testing the same drug.
- NCT03393689 — RGD PET/MRI in Sporadic Vestibular Schwannoma · Phase 2 · unknown
Other recruiting trials for Neuroendocrine Tumors
Currently open trials in the same condition.
- NCT07404176 — Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocr · Phase 2 · recruiting
- NCT07314164 — Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment · recruiting
- NCT07272512 — Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms · Phase 4 · recruiting
- NCT06735560 — Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN · NA · recruiting
- NCT06889493 — SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Dif · Phase 1 · recruiting
Other Rigshospitalet, Denmark trials
Trials by the same sponsor.
- NCT07401368 — Clinicians' Trust in AI-Based Fetal Growth Estimates · NA · not yet recruiting
- NCT07442357 — The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial · NA · not yet recruiting
- NCT07528729 — Alcohol as a Modifiable Risk Factor for Atrial Fibrillation · NA · not yet recruiting
- NCT07511439 — Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission · Phase 4 · not yet recruiting
- NCT07467187 — Invasive Home Ventilation in Denmark · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03271281 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rigshospitalet, Denmark
- Last refreshed: 30 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03271281.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing